nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—HTR7—vas deferens—urinary bladder cancer	0.0481	0.235	CbGeAlD
Asenapine—CYP1A2—urine—urinary bladder cancer	0.00954	0.0466	CbGeAlD
Asenapine—UGT1A4—renal system—urinary bladder cancer	0.00918	0.0449	CbGeAlD
Asenapine—HTR2A—urine—urinary bladder cancer	0.00746	0.0365	CbGeAlD
Asenapine—CYP3A4—urine—urinary bladder cancer	0.00691	0.0338	CbGeAlD
Asenapine—CYP2D6—urine—urinary bladder cancer	0.0068	0.0332	CbGeAlD
Asenapine—ADRB1—prostate gland—urinary bladder cancer	0.00524	0.0256	CbGeAlD
Asenapine—ADRA1A—prostate gland—urinary bladder cancer	0.00414	0.0202	CbGeAlD
Asenapine—ADRA2C—prostate gland—urinary bladder cancer	0.00395	0.0193	CbGeAlD
Asenapine—HTR2B—smooth muscle tissue—urinary bladder cancer	0.00355	0.0174	CbGeAlD
Asenapine—ADRA2C—seminal vesicle—urinary bladder cancer	0.00334	0.0163	CbGeAlD
Asenapine—HRH1—prostate gland—urinary bladder cancer	0.00321	0.0157	CbGeAlD
Asenapine—HTR7—epithelium—urinary bladder cancer	0.00316	0.0154	CbGeAlD
Asenapine—ADRA2A—prostate gland—urinary bladder cancer	0.00315	0.0154	CbGeAlD
Asenapine—HTR1A—renal system—urinary bladder cancer	0.00306	0.015	CbGeAlD
Asenapine—ADRA1A—epithelium—urinary bladder cancer	0.00304	0.0149	CbGeAlD
Asenapine—HTR7—smooth muscle tissue—urinary bladder cancer	0.00304	0.0149	CbGeAlD
Asenapine—HTR1B—female reproductive system—urinary bladder cancer	0.00304	0.0149	CbGeAlD
Asenapine—HTR1D—female reproductive system—urinary bladder cancer	0.00294	0.0144	CbGeAlD
Asenapine—HTR7—renal system—urinary bladder cancer	0.00293	0.0143	CbGeAlD
Asenapine—HTR2C—female reproductive system—urinary bladder cancer	0.00291	0.0142	CbGeAlD
Asenapine—ADRB1—female reproductive system—urinary bladder cancer	0.00286	0.014	CbGeAlD
Asenapine—ADRA1A—renal system—urinary bladder cancer	0.00282	0.0138	CbGeAlD
Asenapine—SLC6A4—female reproductive system—urinary bladder cancer	0.00276	0.0135	CbGeAlD
Asenapine—HTR2B—female reproductive system—urinary bladder cancer	0.00274	0.0134	CbGeAlD
Asenapine—HRH2—lymph node—urinary bladder cancer	0.0027	0.0132	CbGeAlD
Asenapine—ADRA2C—renal system—urinary bladder cancer	0.00269	0.0132	CbGeAlD
Asenapine—ADRA2A—seminal vesicle—urinary bladder cancer	0.00266	0.013	CbGeAlD
Asenapine—ADRA2C—urethra—urinary bladder cancer	0.00264	0.0129	CbGeAlD
Asenapine—HTR2B—vagina—urinary bladder cancer	0.00248	0.0121	CbGeAlD
Asenapine—HRH1—epithelium—urinary bladder cancer	0.00236	0.0115	CbGeAlD
Asenapine—HTR7—female reproductive system—urinary bladder cancer	0.00234	0.0115	CbGeAlD
Asenapine—CYP1A2—renal system—urinary bladder cancer	0.00233	0.0114	CbGeAlD
Asenapine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00227	0.0111	CbGeAlD
Asenapine—HRH1—urethra—urinary bladder cancer	0.00215	0.0105	CbGeAlD
Asenapine—ADRA2A—urethra—urinary bladder cancer	0.00211	0.0103	CbGeAlD
Asenapine—HTR2A—epithelium—urinary bladder cancer	0.00197	0.00962	CbGeAlD
Asenapine—ADRA2C—vagina—urinary bladder cancer	0.00195	0.00953	CbGeAlD
Asenapine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.0019	0.00927	CbGeAlD
Asenapine—HTR2A—renal system—urinary bladder cancer	0.00183	0.00892	CbGeAlD
Asenapine—HRH1—female reproductive system—urinary bladder cancer	0.00175	0.00856	CbGeAlD
Asenapine—ADRA2A—female reproductive system—urinary bladder cancer	0.00172	0.0084	CbGeAlD
Asenapine—CYP3A4—renal system—urinary bladder cancer	0.00169	0.00826	CbGeAlD
Asenapine—CYP2D6—renal system—urinary bladder cancer	0.00166	0.00813	CbGeAlD
Asenapine—HTR2B—lymph node—urinary bladder cancer	0.0016	0.00783	CbGeAlD
Asenapine—HRH1—vagina—urinary bladder cancer	0.00158	0.00774	CbGeAlD
Asenapine—ADRA2A—vagina—urinary bladder cancer	0.00155	0.0076	CbGeAlD
Asenapine—HTR2A—female reproductive system—urinary bladder cancer	0.00146	0.00715	CbGeAlD
Asenapine—CYP3A4—female reproductive system—urinary bladder cancer	0.00135	0.00662	CbGeAlD
Asenapine—CYP2D6—female reproductive system—urinary bladder cancer	0.00133	0.00651	CbGeAlD
Asenapine—HTR2A—vagina—urinary bladder cancer	0.00132	0.00646	CbGeAlD
Asenapine—ADRA2C—lymph node—urinary bladder cancer	0.00126	0.00616	CbGeAlD
Asenapine—Increased appetite—Epirubicin—urinary bladder cancer	0.00109	0.00204	CcSEcCtD
Asenapine—Diabetes mellitus—Doxorubicin—urinary bladder cancer	0.00108	0.00204	CcSEcCtD
Asenapine—Malaise—Cisplatin—urinary bladder cancer	0.00108	0.00203	CcSEcCtD
Asenapine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.00107	0.00202	CcSEcCtD
Asenapine—Fatigue—Thiotepa—urinary bladder cancer	0.00107	0.00202	CcSEcCtD
Asenapine—Dysgeusia—Etoposide—urinary bladder cancer	0.00107	0.00202	CcSEcCtD
Asenapine—Leukopenia—Cisplatin—urinary bladder cancer	0.00107	0.00201	CcSEcCtD
Asenapine—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.00107	0.00201	CcSEcCtD
Asenapine—Constipation—Thiotepa—urinary bladder cancer	0.00106	0.002	CcSEcCtD
Asenapine—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00105	0.00198	CcSEcCtD
Asenapine—Muscle spasms—Etoposide—urinary bladder cancer	0.00105	0.00198	CcSEcCtD
Asenapine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00105	0.00197	CcSEcCtD
Asenapine—Irritability—Methotrexate—urinary bladder cancer	0.00104	0.00195	CcSEcCtD
Asenapine—Convulsion—Cisplatin—urinary bladder cancer	0.00104	0.00195	CcSEcCtD
Asenapine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.00103	0.00193	CcSEcCtD
Asenapine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.00103	0.00193	CcSEcCtD
Asenapine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.00103	0.00193	CcSEcCtD
Asenapine—HRH1—lymph node—urinary bladder cancer	0.00102	0.00501	CbGeAlD
Asenapine—Hyponatraemia—Epirubicin—urinary bladder cancer	0.00102	0.00192	CcSEcCtD
Asenapine—Osteoarthritis—Epirubicin—urinary bladder cancer	0.00102	0.00192	CcSEcCtD
Asenapine—Pain in extremity—Epirubicin—urinary bladder cancer	0.00102	0.00192	CcSEcCtD
Asenapine—Anxiety—Cisplatin—urinary bladder cancer	0.00101	0.00191	CcSEcCtD
Asenapine—Anaemia—Etoposide—urinary bladder cancer	0.00101	0.0019	CcSEcCtD
Asenapine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00101	0.0019	CcSEcCtD
Asenapine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.00101	0.00189	CcSEcCtD
Asenapine—ADRA2A—lymph node—urinary bladder cancer	0.00101	0.00492	CbGeAlD
Asenapine—Tachycardia—Fluorouracil—urinary bladder cancer	0.001	0.00189	CcSEcCtD
Asenapine—Increased appetite—Doxorubicin—urinary bladder cancer	0.001	0.00189	CcSEcCtD
Asenapine—Malaise—Etoposide—urinary bladder cancer	0.000988	0.00186	CcSEcCtD
Asenapine—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.000987	0.00186	CcSEcCtD
Asenapine—Breast disorder—Methotrexate—urinary bladder cancer	0.000985	0.00185	CcSEcCtD
Asenapine—Leukopenia—Etoposide—urinary bladder cancer	0.000981	0.00184	CcSEcCtD
Asenapine—Hypotension—Gemcitabine—urinary bladder cancer	0.000978	0.00184	CcSEcCtD
Asenapine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000976	0.00183	CcSEcCtD
Asenapine—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.000975	0.00183	CcSEcCtD
Asenapine—Loss of consciousness—Etoposide—urinary bladder cancer	0.000963	0.00181	CcSEcCtD
Asenapine—Hypotension—Fluorouracil—urinary bladder cancer	0.000962	0.00181	CcSEcCtD
Asenapine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000957	0.0018	CcSEcCtD
Asenapine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000955	0.0018	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000954	0.00179	CcSEcCtD
Asenapine—Tachycardia—Cisplatin—urinary bladder cancer	0.000952	0.00179	CcSEcCtD
Asenapine—Convulsion—Etoposide—urinary bladder cancer	0.000949	0.00178	CcSEcCtD
Asenapine—Hyponatraemia—Doxorubicin—urinary bladder cancer	0.000947	0.00178	CcSEcCtD
Asenapine—Insomnia—Gemcitabine—urinary bladder cancer	0.000947	0.00178	CcSEcCtD
Asenapine—Hypertension—Etoposide—urinary bladder cancer	0.000946	0.00178	CcSEcCtD
Asenapine—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000943	0.00177	CcSEcCtD
Asenapine—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000943	0.00177	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000938	0.00176	CcSEcCtD
Asenapine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000933	0.00175	CcSEcCtD
Asenapine—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000931	0.00175	CcSEcCtD
Asenapine—Insomnia—Fluorouracil—urinary bladder cancer	0.000931	0.00175	CcSEcCtD
Asenapine—Somnolence—Gemcitabine—urinary bladder cancer	0.000931	0.00175	CcSEcCtD
Asenapine—Breast disorder—Epirubicin—urinary bladder cancer	0.000921	0.00173	CcSEcCtD
Asenapine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000918	0.00172	CcSEcCtD
Asenapine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000917	0.00172	CcSEcCtD
Asenapine—Somnolence—Fluorouracil—urinary bladder cancer	0.000915	0.00172	CcSEcCtD
Asenapine—Hypotension—Cisplatin—urinary bladder cancer	0.000912	0.00171	CcSEcCtD
Asenapine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000906	0.0017	CcSEcCtD
Asenapine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000904	0.0017	CcSEcCtD
Asenapine—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000903	0.0017	CcSEcCtD
Asenapine—Fatigue—Gemcitabine—urinary bladder cancer	0.000903	0.0017	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000899	0.00169	CcSEcCtD
Asenapine—Constipation—Gemcitabine—urinary bladder cancer	0.000895	0.00168	CcSEcCtD
Asenapine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000894	0.00168	CcSEcCtD
Asenapine—Asthenia—Thiotepa—urinary bladder cancer	0.000893	0.00168	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000889	0.00167	CcSEcCtD
Asenapine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000889	0.00167	CcSEcCtD
Asenapine—Dysphagia—Epirubicin—urinary bladder cancer	0.000881	0.00166	CcSEcCtD
Asenapine—Neutropenia—Methotrexate—urinary bladder cancer	0.000881	0.00166	CcSEcCtD
Asenapine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000875	0.00165	CcSEcCtD
Asenapine—Tachycardia—Etoposide—urinary bladder cancer	0.000873	0.00164	CcSEcCtD
Asenapine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00087	0.00164	CcSEcCtD
Asenapine—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000862	0.00162	CcSEcCtD
Asenapine—Breast disorder—Doxorubicin—urinary bladder cancer	0.000853	0.0016	CcSEcCtD
Asenapine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000842	0.00158	CcSEcCtD
Asenapine—Depression—Methotrexate—urinary bladder cancer	0.000837	0.00157	CcSEcCtD
Asenapine—Hypotension—Etoposide—urinary bladder cancer	0.000835	0.00157	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000832	0.00156	CcSEcCtD
Asenapine—Neutropenia—Epirubicin—urinary bladder cancer	0.000824	0.00155	CcSEcCtD
Asenapine—Dizziness—Thiotepa—urinary bladder cancer	0.000823	0.00155	CcSEcCtD
Asenapine—Stomatitis—Methotrexate—urinary bladder cancer	0.000818	0.00154	CcSEcCtD
Asenapine—Dysphagia—Doxorubicin—urinary bladder cancer	0.000815	0.00153	CcSEcCtD
Asenapine—Weight increased—Epirubicin—urinary bladder cancer	0.000802	0.00151	CcSEcCtD
Asenapine—Dyspnoea—Etoposide—urinary bladder cancer	0.000797	0.0015	CcSEcCtD
Asenapine—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000795	0.00149	CcSEcCtD
Asenapine—Somnolence—Etoposide—urinary bladder cancer	0.000795	0.00149	CcSEcCtD
Asenapine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000794	0.00149	CcSEcCtD
Asenapine—Vomiting—Thiotepa—urinary bladder cancer	0.000791	0.00149	CcSEcCtD
Asenapine—Rash—Thiotepa—urinary bladder cancer	0.000785	0.00147	CcSEcCtD
Asenapine—Dermatitis—Thiotepa—urinary bladder cancer	0.000784	0.00147	CcSEcCtD
Asenapine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000784	0.00147	CcSEcCtD
Asenapine—Headache—Thiotepa—urinary bladder cancer	0.00078	0.00147	CcSEcCtD
Asenapine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000772	0.00145	CcSEcCtD
Asenapine—Fatigue—Etoposide—urinary bladder cancer	0.000771	0.00145	CcSEcCtD
Asenapine—Stomatitis—Epirubicin—urinary bladder cancer	0.000766	0.00144	CcSEcCtD
Asenapine—Constipation—Etoposide—urinary bladder cancer	0.000765	0.00144	CcSEcCtD
Asenapine—Neutropenia—Doxorubicin—urinary bladder cancer	0.000762	0.00143	CcSEcCtD
Asenapine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000758	0.00143	CcSEcCtD
Asenapine—Asthenia—Gemcitabine—urinary bladder cancer	0.000751	0.00141	CcSEcCtD
Asenapine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000743	0.0014	CcSEcCtD
Asenapine—Weight increased—Doxorubicin—urinary bladder cancer	0.000742	0.00139	CcSEcCtD
Asenapine—Nausea—Thiotepa—urinary bladder cancer	0.000739	0.00139	CcSEcCtD
Asenapine—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000736	0.00138	CcSEcCtD
Asenapine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000733	0.00138	CcSEcCtD
Asenapine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000719	0.00135	CcSEcCtD
Asenapine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000709	0.00133	CcSEcCtD
Asenapine—Eye disorder—Methotrexate—urinary bladder cancer	0.000704	0.00132	CcSEcCtD
Asenapine—Asthenia—Cisplatin—urinary bladder cancer	0.0007	0.00132	CcSEcCtD
Asenapine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.0007	0.00131	CcSEcCtD
Asenapine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000695	0.00131	CcSEcCtD
Asenapine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000693	0.0013	CcSEcCtD
Asenapine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000688	0.00129	CcSEcCtD
Asenapine—Angiopathy—Methotrexate—urinary bladder cancer	0.000684	0.00129	CcSEcCtD
Asenapine—Immune system disorder—Methotrexate—urinary bladder cancer	0.000681	0.00128	CcSEcCtD
Asenapine—Dizziness—Fluorouracil—urinary bladder cancer	0.000681	0.00128	CcSEcCtD
Asenapine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000679	0.00128	CcSEcCtD
Asenapine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000678	0.00128	CcSEcCtD
Asenapine—Vomiting—Gemcitabine—urinary bladder cancer	0.000666	0.00125	CcSEcCtD
Asenapine—Mental disorder—Methotrexate—urinary bladder cancer	0.00066	0.00124	CcSEcCtD
Asenapine—Rash—Gemcitabine—urinary bladder cancer	0.00066	0.00124	CcSEcCtD
Asenapine—Dermatitis—Gemcitabine—urinary bladder cancer	0.00066	0.00124	CcSEcCtD
Asenapine—Eye disorder—Epirubicin—urinary bladder cancer	0.000659	0.00124	CcSEcCtD
Asenapine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000659	0.00124	CcSEcCtD
Asenapine—Malnutrition—Methotrexate—urinary bladder cancer	0.000656	0.00123	CcSEcCtD
Asenapine—Headache—Gemcitabine—urinary bladder cancer	0.000656	0.00123	CcSEcCtD
Asenapine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000655	0.00123	CcSEcCtD
Asenapine—Vomiting—Fluorouracil—urinary bladder cancer	0.000655	0.00123	CcSEcCtD
Asenapine—Rash—Fluorouracil—urinary bladder cancer	0.000649	0.00122	CcSEcCtD
Asenapine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000648	0.00122	CcSEcCtD
Asenapine—Headache—Fluorouracil—urinary bladder cancer	0.000645	0.00121	CcSEcCtD
Asenapine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000643	0.00121	CcSEcCtD
Asenapine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000643	0.00121	CcSEcCtD
Asenapine—Asthenia—Etoposide—urinary bladder cancer	0.000641	0.00121	CcSEcCtD
Asenapine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000641	0.00121	CcSEcCtD
Asenapine—Angiopathy—Epirubicin—urinary bladder cancer	0.00064	0.0012	CcSEcCtD
Asenapine—Immune system disorder—Epirubicin—urinary bladder cancer	0.000637	0.0012	CcSEcCtD
Asenapine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000636	0.00119	CcSEcCtD
Asenapine—Nausea—Gemcitabine—urinary bladder cancer	0.000622	0.00117	CcSEcCtD
Asenapine—Vomiting—Cisplatin—urinary bladder cancer	0.00062	0.00117	CcSEcCtD
Asenapine—Mental disorder—Epirubicin—urinary bladder cancer	0.000618	0.00116	CcSEcCtD
Asenapine—Rash—Cisplatin—urinary bladder cancer	0.000615	0.00116	CcSEcCtD
Asenapine—Dermatitis—Cisplatin—urinary bladder cancer	0.000615	0.00116	CcSEcCtD
Asenapine—Malnutrition—Epirubicin—urinary bladder cancer	0.000614	0.00115	CcSEcCtD
Asenapine—Nausea—Fluorouracil—urinary bladder cancer	0.000611	0.00115	CcSEcCtD
Asenapine—Eye disorder—Doxorubicin—urinary bladder cancer	0.00061	0.00115	CcSEcCtD
Asenapine—Anaemia—Methotrexate—urinary bladder cancer	0.000606	0.00114	CcSEcCtD
Asenapine—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000606	0.00114	CcSEcCtD
Asenapine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000601	0.00113	CcSEcCtD
Asenapine—Angiopathy—Doxorubicin—urinary bladder cancer	0.000592	0.00111	CcSEcCtD
Asenapine—Malaise—Methotrexate—urinary bladder cancer	0.000592	0.00111	CcSEcCtD
Asenapine—Dizziness—Etoposide—urinary bladder cancer	0.000591	0.00111	CcSEcCtD
Asenapine—Muscle spasms—Epirubicin—urinary bladder cancer	0.00059	0.00111	CcSEcCtD
Asenapine—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00059	0.00111	CcSEcCtD
Asenapine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000588	0.00111	CcSEcCtD
Asenapine—Leukopenia—Methotrexate—urinary bladder cancer	0.000587	0.0011	CcSEcCtD
Asenapine—Nausea—Cisplatin—urinary bladder cancer	0.00058	0.00109	CcSEcCtD
Asenapine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000572	0.00107	CcSEcCtD
Asenapine—Convulsion—Methotrexate—urinary bladder cancer	0.000568	0.00107	CcSEcCtD
Asenapine—Vomiting—Etoposide—urinary bladder cancer	0.000568	0.00107	CcSEcCtD
Asenapine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000568	0.00107	CcSEcCtD
Asenapine—Anaemia—Epirubicin—urinary bladder cancer	0.000568	0.00107	CcSEcCtD
Asenapine—Agitation—Epirubicin—urinary bladder cancer	0.000564	0.00106	CcSEcCtD
Asenapine—Rash—Etoposide—urinary bladder cancer	0.000564	0.00106	CcSEcCtD
Asenapine—Dermatitis—Etoposide—urinary bladder cancer	0.000563	0.00106	CcSEcCtD
Asenapine—Headache—Etoposide—urinary bladder cancer	0.00056	0.00105	CcSEcCtD
Asenapine—Arthralgia—Methotrexate—urinary bladder cancer	0.000559	0.00105	CcSEcCtD
Asenapine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000556	0.00105	CcSEcCtD
Asenapine—Malaise—Epirubicin—urinary bladder cancer	0.000554	0.00104	CcSEcCtD
Asenapine—Syncope—Epirubicin—urinary bladder cancer	0.000551	0.00103	CcSEcCtD
Asenapine—Leukopenia—Epirubicin—urinary bladder cancer	0.00055	0.00103	CcSEcCtD
Asenapine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000546	0.00103	CcSEcCtD
Asenapine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.00054	0.00101	CcSEcCtD
Asenapine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000536	0.00101	CcSEcCtD
Asenapine—Convulsion—Epirubicin—urinary bladder cancer	0.000532	0.001	CcSEcCtD
Asenapine—Nausea—Etoposide—urinary bladder cancer	0.000531	0.000998	CcSEcCtD
Asenapine—Hypertension—Epirubicin—urinary bladder cancer	0.00053	0.000996	CcSEcCtD
Asenapine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000525	0.000987	CcSEcCtD
Asenapine—Anaemia—Doxorubicin—urinary bladder cancer	0.000525	0.000987	CcSEcCtD
Asenapine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000524	0.000985	CcSEcCtD
Asenapine—Arthralgia—Epirubicin—urinary bladder cancer	0.000523	0.000983	CcSEcCtD
Asenapine—Agitation—Doxorubicin—urinary bladder cancer	0.000522	0.000981	CcSEcCtD
Asenapine—Anxiety—Epirubicin—urinary bladder cancer	0.000521	0.000979	CcSEcCtD
Asenapine—Malaise—Doxorubicin—urinary bladder cancer	0.000512	0.000963	CcSEcCtD
Asenapine—Dry mouth—Epirubicin—urinary bladder cancer	0.000511	0.000961	CcSEcCtD
Asenapine—Syncope—Doxorubicin—urinary bladder cancer	0.00051	0.000958	CcSEcCtD
Asenapine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000509	0.000956	CcSEcCtD
Asenapine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000501	0.000942	CcSEcCtD
Asenapine—Hypotension—Methotrexate—urinary bladder cancer	0.0005	0.00094	CcSEcCtD
Asenapine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000499	0.000939	CcSEcCtD
Asenapine—Shock—Epirubicin—urinary bladder cancer	0.000493	0.000927	CcSEcCtD
Asenapine—Convulsion—Doxorubicin—urinary bladder cancer	0.000492	0.000925	CcSEcCtD
Asenapine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000491	0.000924	CcSEcCtD
Asenapine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000491	0.000922	CcSEcCtD
Asenapine—Hypertension—Doxorubicin—urinary bladder cancer	0.000491	0.000922	CcSEcCtD
Asenapine—Tachycardia—Epirubicin—urinary bladder cancer	0.000489	0.000919	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000488	0.000917	CcSEcCtD
Asenapine—Insomnia—Methotrexate—urinary bladder cancer	0.000484	0.00091	CcSEcCtD
Asenapine—Arthralgia—Doxorubicin—urinary bladder cancer	0.000484	0.000909	CcSEcCtD
Asenapine—Anxiety—Doxorubicin—urinary bladder cancer	0.000482	0.000906	CcSEcCtD
Asenapine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000477	0.000897	CcSEcCtD
Asenapine—Somnolence—Methotrexate—urinary bladder cancer	0.000476	0.000895	CcSEcCtD
Asenapine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000473	0.000889	CcSEcCtD
Asenapine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000471	0.000886	CcSEcCtD
Asenapine—Hypotension—Epirubicin—urinary bladder cancer	0.000468	0.00088	CcSEcCtD
Asenapine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000464	0.000872	CcSEcCtD
Asenapine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000462	0.000869	CcSEcCtD
Asenapine—Fatigue—Methotrexate—urinary bladder cancer	0.000462	0.000868	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000457	0.000858	CcSEcCtD
Asenapine—Shock—Doxorubicin—urinary bladder cancer	0.000456	0.000857	CcSEcCtD
Asenapine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000455	0.000855	CcSEcCtD
Asenapine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000454	0.000853	CcSEcCtD
Asenapine—Insomnia—Epirubicin—urinary bladder cancer	0.000453	0.000852	CcSEcCtD
Asenapine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000453	0.000851	CcSEcCtD
Asenapine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000447	0.00084	CcSEcCtD
Asenapine—Somnolence—Epirubicin—urinary bladder cancer	0.000446	0.000837	CcSEcCtD
Asenapine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000441	0.000829	CcSEcCtD
Asenapine—Hypotension—Doxorubicin—urinary bladder cancer	0.000433	0.000814	CcSEcCtD
Asenapine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000433	0.000813	CcSEcCtD
Asenapine—Fatigue—Epirubicin—urinary bladder cancer	0.000432	0.000812	CcSEcCtD
Asenapine—Constipation—Epirubicin—urinary bladder cancer	0.000429	0.000805	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000422	0.000794	CcSEcCtD
Asenapine—Insomnia—Doxorubicin—urinary bladder cancer	0.000419	0.000788	CcSEcCtD
Asenapine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000413	0.000777	CcSEcCtD
Asenapine—Somnolence—Doxorubicin—urinary bladder cancer	0.000412	0.000775	CcSEcCtD
Asenapine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000408	0.000767	CcSEcCtD
Asenapine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.0004	0.000752	CcSEcCtD
Asenapine—Fatigue—Doxorubicin—urinary bladder cancer	0.0004	0.000751	CcSEcCtD
Asenapine—Constipation—Doxorubicin—urinary bladder cancer	0.000397	0.000745	CcSEcCtD
Asenapine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000395	0.000742	CcSEcCtD
Asenapine—Asthenia—Methotrexate—urinary bladder cancer	0.000384	0.000722	CcSEcCtD
Asenapine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000369	0.000694	CcSEcCtD
Asenapine—Asthenia—Epirubicin—urinary bladder cancer	0.00036	0.000676	CcSEcCtD
Asenapine—Dizziness—Methotrexate—urinary bladder cancer	0.000354	0.000666	CcSEcCtD
Asenapine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000342	0.000642	CcSEcCtD
Asenapine—Vomiting—Methotrexate—urinary bladder cancer	0.00034	0.00064	CcSEcCtD
Asenapine—Rash—Methotrexate—urinary bladder cancer	0.000338	0.000635	CcSEcCtD
Asenapine—Dermatitis—Methotrexate—urinary bladder cancer	0.000337	0.000634	CcSEcCtD
Asenapine—Headache—Methotrexate—urinary bladder cancer	0.000335	0.000631	CcSEcCtD
Asenapine—Asthenia—Doxorubicin—urinary bladder cancer	0.000333	0.000625	CcSEcCtD
Asenapine—Dizziness—Epirubicin—urinary bladder cancer	0.000331	0.000623	CcSEcCtD
Asenapine—Vomiting—Epirubicin—urinary bladder cancer	0.000319	0.000599	CcSEcCtD
Asenapine—Nausea—Methotrexate—urinary bladder cancer	0.000318	0.000598	CcSEcCtD
Asenapine—Rash—Epirubicin—urinary bladder cancer	0.000316	0.000594	CcSEcCtD
Asenapine—Dermatitis—Epirubicin—urinary bladder cancer	0.000316	0.000593	CcSEcCtD
Asenapine—Headache—Epirubicin—urinary bladder cancer	0.000314	0.00059	CcSEcCtD
Asenapine—Dizziness—Doxorubicin—urinary bladder cancer	0.000307	0.000576	CcSEcCtD
Asenapine—Nausea—Epirubicin—urinary bladder cancer	0.000298	0.000559	CcSEcCtD
Asenapine—Vomiting—Doxorubicin—urinary bladder cancer	0.000295	0.000554	CcSEcCtD
Asenapine—Rash—Doxorubicin—urinary bladder cancer	0.000292	0.00055	CcSEcCtD
Asenapine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000292	0.000549	CcSEcCtD
Asenapine—Headache—Doxorubicin—urinary bladder cancer	0.00029	0.000546	CcSEcCtD
Asenapine—Nausea—Doxorubicin—urinary bladder cancer	0.000275	0.000518	CcSEcCtD
Asenapine—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	2.17e-05	8.23e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—SRC—urinary bladder cancer	2.17e-05	8.22e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—KRAS—urinary bladder cancer	2.16e-05	8.21e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CXCL8—urinary bladder cancer	2.15e-05	8.18e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—ERBB2—urinary bladder cancer	2.15e-05	8.16e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling by GPCR—HRAS—urinary bladder cancer	2.14e-05	8.13e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.13e-05	8.07e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—MYC—urinary bladder cancer	2.13e-05	8.07e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—MYC—urinary bladder cancer	2.12e-05	8.06e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	2.12e-05	8.06e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	2.11e-05	8.01e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—RHOA—urinary bladder cancer	2.11e-05	8e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	2.11e-05	8e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.1e-05	7.99e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL2—urinary bladder cancer	2.1e-05	7.99e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—EP300—urinary bladder cancer	2.1e-05	7.97e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CXCL8—urinary bladder cancer	2.1e-05	7.96e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	2.09e-05	7.94e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—EP300—urinary bladder cancer	2.09e-05	7.94e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.09e-05	7.92e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	2.09e-05	7.92e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.08e-05	7.91e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	2.08e-05	7.91e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling by GPCR—HRAS—urinary bladder cancer	2.08e-05	7.9e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—EGFR—urinary bladder cancer	2.08e-05	7.9e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—EGFR—urinary bladder cancer	2.08e-05	7.89e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	2.07e-05	7.87e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—EP300—urinary bladder cancer	2.07e-05	7.87e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	2.07e-05	7.85e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—MYC—urinary bladder cancer	2.07e-05	7.84e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	2.06e-05	7.84e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL2—urinary bladder cancer	2.06e-05	7.82e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	2.06e-05	7.82e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CCND1—urinary bladder cancer	2.05e-05	7.79e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.05e-05	7.78e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—SRC—urinary bladder cancer	2.04e-05	7.75e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	2.04e-05	7.75e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CXCL8—urinary bladder cancer	2.04e-05	7.74e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—MYC—urinary bladder cancer	2.03e-05	7.72e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	2.03e-05	7.72e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	2.03e-05	7.71e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling by GPCR—HRAS—urinary bladder cancer	2.02e-05	7.69e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.02e-05	7.68e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—EGFR—urinary bladder cancer	2.02e-05	7.67e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—SRC—urinary bladder cancer	2.02e-05	7.65e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	2.01e-05	7.64e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.01e-05	7.64e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CCND1—urinary bladder cancer	2.01e-05	7.62e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL2—urinary bladder cancer	2e-05	7.6e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2e-05	7.59e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2e-05	7.59e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MMP9—urinary bladder cancer	1.99e-05	7.56e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—EGFR—urinary bladder cancer	1.99e-05	7.55e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.98e-05	7.53e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PTEN—urinary bladder cancer	1.98e-05	7.52e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	1.97e-05	7.49e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	1.97e-05	7.47e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—KRAS—urinary bladder cancer	1.96e-05	7.46e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—KRAS—urinary bladder cancer	1.96e-05	7.45e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	1.96e-05	7.45e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	1.96e-05	7.45e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CCND1—urinary bladder cancer	1.95e-05	7.41e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—ERBB2—urinary bladder cancer	1.95e-05	7.4e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	1.95e-05	7.4e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MMP9—urinary bladder cancer	1.95e-05	7.4e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL2—urinary bladder cancer	1.95e-05	7.39e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.94e-05	7.37e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—MYC—urinary bladder cancer	1.94e-05	7.37e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PTEN—urinary bladder cancer	1.94e-05	7.35e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	1.93e-05	7.35e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.92e-05	7.28e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	1.91e-05	7.27e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	1.91e-05	7.27e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—KRAS—urinary bladder cancer	1.91e-05	7.25e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	1.9e-05	7.23e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CCND1—urinary bladder cancer	1.9e-05	7.21e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—EGFR—urinary bladder cancer	1.9e-05	7.21e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.9e-05	7.21e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MMP9—urinary bladder cancer	1.9e-05	7.2e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	1.89e-05	7.19e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.89e-05	7.17e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EP300—urinary bladder cancer	1.89e-05	7.17e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	1.89e-05	7.16e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PTEN—urinary bladder cancer	1.88e-05	7.15e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	1.88e-05	7.14e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	1.88e-05	7.13e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—KRAS—urinary bladder cancer	1.88e-05	7.13e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	1.87e-05	7.1e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CXCL8—urinary bladder cancer	1.85e-05	7.02e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EP300—urinary bladder cancer	1.85e-05	7.01e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MMP9—urinary bladder cancer	1.84e-05	7e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—HRAS—urinary bladder cancer	1.84e-05	6.98e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—CDKN1A—urinary bladder cancer	1.84e-05	6.97e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—SRC—urinary bladder cancer	1.84e-05	6.97e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PTEN—urinary bladder cancer	1.83e-05	6.96e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—MYC—urinary bladder cancer	1.83e-05	6.95e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.82e-05	6.91e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	1.82e-05	6.91e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	1.82e-05	6.89e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.81e-05	6.86e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	1.81e-05	6.86e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—MYC—urinary bladder cancer	1.81e-05	6.86e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	1.8e-05	6.85e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EP300—urinary bladder cancer	1.8e-05	6.82e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—SRC—urinary bladder cancer	1.8e-05	6.82e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—KRAS—urinary bladder cancer	1.79e-05	6.81e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—EGFR—urinary bladder cancer	1.79e-05	6.8e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	1.78e-05	6.76e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PTEN—urinary bladder cancer	1.78e-05	6.76e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	1.77e-05	6.72e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL2—urinary bladder cancer	1.77e-05	6.71e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	1.77e-05	6.71e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—EGFR—urinary bladder cancer	1.77e-05	6.71e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	1.76e-05	6.67e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EP300—urinary bladder cancer	1.75e-05	6.64e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—SRC—urinary bladder cancer	1.75e-05	6.63e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—TP53—urinary bladder cancer	1.75e-05	6.63e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	1.75e-05	6.63e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—TP53—urinary bladder cancer	1.74e-05	6.62e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	1.74e-05	6.6e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	1.74e-05	6.59e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	1.73e-05	6.58e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CCND1—urinary bladder cancer	1.72e-05	6.54e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	1.7e-05	6.46e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—SRC—urinary bladder cancer	1.7e-05	6.45e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—EP300—urinary bladder cancer	1.7e-05	6.45e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—urinary bladder cancer	1.7e-05	6.44e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	1.7e-05	6.44e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	1.69e-05	6.42e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—urinary bladder cancer	1.69e-05	6.42e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.69e-05	6.42e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.68e-05	6.37e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MMP9—urinary bladder cancer	1.67e-05	6.35e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—urinary bladder cancer	1.67e-05	6.34e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—urinary bladder cancer	1.67e-05	6.34e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—urinary bladder cancer	1.67e-05	6.34e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—urinary bladder cancer	1.67e-05	6.33e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1A—urinary bladder cancer	1.67e-05	6.33e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—urinary bladder cancer	1.66e-05	6.31e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	1.66e-05	6.3e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	1.66e-05	6.29e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	1.66e-05	6.29e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	1.65e-05	6.25e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—urinary bladder cancer	1.65e-05	6.25e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	1.64e-05	6.24e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	1.64e-05	6.24e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.64e-05	6.23e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.64e-05	6.21e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	1.64e-05	6.21e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	1.63e-05	6.2e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	1.63e-05	6.19e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.62e-05	6.17e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—urinary bladder cancer	1.62e-05	6.16e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	1.61e-05	6.12e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—urinary bladder cancer	1.61e-05	6.11e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EGFR—urinary bladder cancer	1.61e-05	6.11e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.61e-05	6.1e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	1.6e-05	6.08e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—urinary bladder cancer	1.6e-05	6.06e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	1.59e-05	6.05e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—urinary bladder cancer	1.59e-05	6.05e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EP300—urinary bladder cancer	1.59e-05	6.02e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	1.58e-05	6.01e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EGFR—urinary bladder cancer	1.57e-05	5.98e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	1.57e-05	5.98e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—urinary bladder cancer	1.57e-05	5.94e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.56e-05	5.93e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	1.56e-05	5.92e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	1.56e-05	5.91e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.54e-05	5.86e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.54e-05	5.86e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	1.54e-05	5.86e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—SRC—urinary bladder cancer	1.54e-05	5.85e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	1.54e-05	5.84e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EGFR—urinary bladder cancer	1.53e-05	5.81e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	1.53e-05	5.8e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—urinary bladder cancer	1.52e-05	5.79e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—urinary bladder cancer	1.52e-05	5.78e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—urinary bladder cancer	1.52e-05	5.77e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.52e-05	5.76e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	1.51e-05	5.75e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	1.51e-05	5.72e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—urinary bladder cancer	1.5e-05	5.71e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	1.5e-05	5.68e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	1.49e-05	5.66e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EGFR—urinary bladder cancer	1.49e-05	5.66e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	1.49e-05	5.65e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—urinary bladder cancer	1.49e-05	5.65e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	1.49e-05	5.64e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—urinary bladder cancer	1.48e-05	5.63e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.48e-05	5.61e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	1.45e-05	5.52e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.45e-05	5.51e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—urinary bladder cancer	1.45e-05	5.49e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—urinary bladder cancer	1.44e-05	5.46e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.43e-05	5.44e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	1.42e-05	5.39e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—urinary bladder cancer	1.42e-05	5.39e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—urinary bladder cancer	1.41e-05	5.34e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—urinary bladder cancer	1.38e-05	5.25e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	1.38e-05	5.24e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.38e-05	5.22e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.36e-05	5.18e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.36e-05	5.16e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	1.36e-05	5.15e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EGFR—urinary bladder cancer	1.35e-05	5.13e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—urinary bladder cancer	1.35e-05	5.13e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	1.34e-05	5.08e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	1.33e-05	5.05e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.33e-05	5.05e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	5.05e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	1.33e-05	5.04e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—urinary bladder cancer	1.32e-05	5.02e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	1.3e-05	4.94e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	1.29e-05	4.91e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—urinary bladder cancer	1.29e-05	4.91e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—urinary bladder cancer	1.29e-05	4.88e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	1.28e-05	4.86e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—urinary bladder cancer	1.28e-05	4.85e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—urinary bladder cancer	1.26e-05	4.8e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.26e-05	4.77e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	1.25e-05	4.76e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—urinary bladder cancer	1.25e-05	4.75e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	1.24e-05	4.7e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	1.24e-05	4.69e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	1.23e-05	4.67e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—urinary bladder cancer	1.23e-05	4.67e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	1.21e-05	4.59e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—urinary bladder cancer	1.2e-05	4.54e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.16e-05	4.4e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	1.14e-05	4.34e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—urinary bladder cancer	1.13e-05	4.31e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.13e-05	4.28e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	1.12e-05	4.24e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	1.11e-05	4.23e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.11e-05	4.2e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.11e-05	4.2e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	1.09e-05	4.15e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—urinary bladder cancer	1.09e-05	4.12e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-05	4.05e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	1.07e-05	4.05e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.06e-05	4.03e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	1.05e-05	3.97e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	1.02e-05	3.86e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	9.83e-06	3.73e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	9.72e-06	3.69e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—EP300—urinary bladder cancer	9.37e-06	3.56e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	8.7e-06	3.3e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	7.58e-06	2.88e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—EP300—urinary bladder cancer	7.23e-06	2.75e-05	CbGpPWpGaD
